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Biological agents are currently a very important option for
refractory autoimmune diseases [1]. From about ten years
to now, several drugs are available to the clinical practice,
mainly, in the rheumatology one. The main biological agents
are antitumor necrosis factor (anti-TNF) medications, how-
ever there are other important drugs such as rituximab,
which blocks lymphocyte B CD20, tocilizumab that inhibits
anti-interleukin-6receptor[2,3].Inthisspecialissueonbio-
logicals from Autoimmune Diseases journal, we have invited
several papers that address this modern issue.
The paper entitled “Biological therapy systemic lupus
erythematosus” of this issue addresses the rational for the
use of biological agents in patients with systemic lupus ery-
thematosus. Several aspects including anti-CD20 and anti-
CD22 antibodies, B-cell tolerogens, costimulatory blockers,
anti-TNF, anti-interferon, anti-interleukins 1, 10, and 18,
and also complement inhibitors. The paper entitled “Use
of biological agents in ocular manifestations of rheuma-
tic disease” reviews the diﬀerent studies published in the lit-
erature regarding biological agents use on ocular disorders.
Thepaperentitled“Tocilizumabforthetreatmentofrheu-
matoid arthritis and other systemic autoimmune diseases: cur-
rent perspective and future directions” is not only an elegant
review of the use of tocilizumab in rheumatoid arthritis, but
also in other autoimmune diseases such as lupus, systemic
sclerosis, polymyositis and large vessel vasculitis.
Complications related to biologicals are discussed in this
paper entitled “Risk of orthopedic site surgical infections in
patients with rheumatoid arthritis treated with anti-tumor
necrosis factor alfa therapy.” The authors performed a lit-
erature review of infections associated to orthopedic sur-
gery in rheumatoid arthritis patients treated with anti-TNF
and found inconclusive data in this ﬁeld.
An experimental study was presented on the paper enti-
tled “TNF-alpha in the locomotor system beyond joints: high
degree of involvement in myositis in a rabbit model.” In this
research paper, the authors have evaluated the role of TNF
in an experimental model of myositis and found interest-
ing results.
The paper entitled “Immunosuppresive exosome: a new
approaching for treating arthritis” brings a new methodology
for treating arthritis. The rational consists that some vesicles
derived from immunosuppressive dendritc cell may have im-
mune suppressive properties and the authors reviewed sev-
eral studies developed by themselves and others that used
these vesicles (exosomes) as in experimental animals as in
humans with the objective of treatment of arthritis.
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